According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4) receptor blockers. The medication is not available in a biosimilar version. Read on for more information about Dupixent.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of anti-inflammatory drug Dupixent rose 15% to $3.7 billion. The French partner, Sanofi, records Dupixent's sales and the profits are split equally between the companies. Its skin cancer ...